ArticleEmerging infectious diseases2022
Economic Burden of Reported Lyme Disease in High-Incidence Areas, United States, 2014-2016.
Article in Emerging infectious diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed.
- When Clades Collide: Genomic Admixture in Blacklegged Ticks (Ixodes scapularis) From the Great Plains.Molecular ecology · 2026Article
- Antiphospholipid antibodies in acute and post-treatment Lyme disease.Infection and immunity · 2026Article
- Harnessing survey data across multiple demographic groups in Illinois to assess survey questions and reveal insights about ticks and tick-borne disease risk: a meta-comparison study.BMC public health · 2026Article
- Contrasting epigenetics of Ixodes scapularis populations.Scientific reports · 2026Article
- Global, regional, and national disease burden of arthropod-borne diseases: Projections to 2030 based on the global burden of disease study 2021.PLoS neglected tropical diseases · 2026Article
- Promoting a Positive Relationship Between Physicians and Patients with Lyme Disease During Pregnancy and Parenthood.Pathogens (Basel, Switzerland) · 2026Article
- Ticks and tick-borne diseases: A call for comprehensive tick surveillance in India under One Health approach.The Indian journal of medical research · 2026Review
- In Silico-Identified Peptides of FiveBiology · 2026Article
- Article
- Post-Exposure Prophylaxis Prescribing Practices in a Lyme Disease-Endemic Area.Infectious disease reports · 2026Article
- Lyme Disease and Health Care Costs.JAMA network open · 2026Article
- Patient roadmap and economic burden of chronic tick-borne illness and post-treatment Lyme disease syndrome in Ireland, and public health issues arising.Frontiers in public health · 2026Article
- Parasitiformes (ticks) and Acariformes (mites) vectors and their vertebrate host diversity: A global scoping review.One health (Amsterdam, Netherlands) · 2025Review
- Harnessing 50 years of tick population genetics: Choosing the right molecular tool for contemporary research.The Journal of animal ecology · 2025Review
- Lyme disease vaccine acceptability among healthcare providers - United States, 2018 and 2022.Vaccine · 2025Article
- Climate differentially impacts ticks infected and uninfected withScience advances · 2025Article
- Spring fever: early spring predicts Ixodes pacificus (Acari: Ixodidae) activity in northwestern California.Journal of medical entomology · 2025Article
- The Current and Future Burden of Long COVID in the United States.The Journal of infectious diseases · 2025Article
- Tick Control Strategies: Critical Insights into Chemical, Biological, Physical, and Integrated Approaches for Effective Hard Tick Management.Veterinary sciences · 2025Review
- Quantifying the Public Health Impact of Lyme Disease in Minnesota: A Simulation Analysis of Reported and Unreported Cases.Journal of health economics and outcomes research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Approximately 476,000 cases of Lyme disease are diagnosed in the United States annually, yet comprehensive economic evaluations are lacking. In a prospective study among reported cases in Lyme disease-endemic states, we estimated the total patient cost and total societal cost of the disease. In addition, we evaluated disease and demographic factors associated with total societal cost. Participants had a mean patient cost of ≈$1,200 (median $240) and a mean societal cost of ≈$2,000 (median $700). Patients with confirmed disseminated disease or probable disease had approximately double the societal cost of those with confirmed localized disease. The annual, aggregate cost of diagnosed Lyme disease could be $345-968 million (2016 US dollars) to US society. Our findings emphasize the importance of effective prevention and early diagnosis to reduce illness and associated costs. These results can be used in cost-effectiveness analyses of current and future prevention methods, such as a vaccine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.